332 related articles for article (PubMed ID: 29202874)
1. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
Gibson RM; Nickel G; Crawford M; Kyeyune F; Venner C; Nankya I; Nabulime E; Ndashimye E; Poon AFY; Salata RA; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
Infect Dis Poverty; 2017 Dec; 6(1):163. PubMed ID: 29202874
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Ayitewala A; Kyeyune F; Ainembabazi P; Nabulime E; Kato CD; Nankya I
AIDS Res Ther; 2020 Jan; 17(1):2. PubMed ID: 32005262
[TBL] [Abstract][Full Text] [Related]
3. K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.
Recordon-Pinson P; Papuchon J; Reigadas S; Deshpande A; Fleury H
PLoS One; 2012; 7(5):e36549. PubMed ID: 22615779
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
[TBL] [Abstract][Full Text] [Related]
6. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
[TBL] [Abstract][Full Text] [Related]
8. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
9. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Aug; (8):CD008651. PubMed ID: 20687097
[TBL] [Abstract][Full Text] [Related]
10. Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01_AE.
Praparattanapan J; Kotarathitithum W; Chaiwarith R; Nuntachit N; Sirisanthana T; Supparatpinyo K
Curr HIV Res; 2012 Dec; 10(8):647-52. PubMed ID: 23061604
[TBL] [Abstract][Full Text] [Related]
11. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y
J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320
[TBL] [Abstract][Full Text] [Related]
12. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
Liu P; Liao L; Xu W; Yan J; Zuo Z; Leng X; Wang J; Kan W; You Y; Xing H; Ruan Y; Shao Y
Medicine (Baltimore); 2018 Dec; 97(50):e13555. PubMed ID: 30558015
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
[TBL] [Abstract][Full Text] [Related]
14. Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
Ndembi N; Murtala-Ibrahim F; Tola M; Jumare J; Aliyu A; Alabi P; Mensah C; Abimiku A; Quiñones-Mateu ME; Crowell TA; Rhee SY; Shafer RW; Gupta R; Blattner W; Charurat ME; Dakum P
AIDS Res Ther; 2020 Nov; 17(1):64. PubMed ID: 33143751
[TBL] [Abstract][Full Text] [Related]
15. Dethroning AZT.
Gilden D; Falkenberg J; Torres G
GMHC Treat Issues; 1997 Feb; 11(2):10-3. PubMed ID: 11364106
[TBL] [Abstract][Full Text] [Related]
16. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
17. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
19. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
Kamya MR; Mayanja-Kizza H; Kambugu A; Bakeera-Kitaka S; Semitala F; Mwebaze-Songa P; Castelnuovo B; Schaefer P; Spacek LA; Gasasira AF; Katabira E; Colebunders R; Quinn TC; Ronald A; Thomas DL; Kekitiinwa A;
J Acquir Immune Defic Syndr; 2007 Oct; 46(2):187-93. PubMed ID: 17693883
[TBL] [Abstract][Full Text] [Related]
20. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
